NeoGenomics Inc (NEO)

Currency in USD
6.24
-0.48(-7.14%)
Closed·
After Hours
6.30+0.06(+0.96%)
·
NEO Scorecard
Full Analysis
Net income is expected to grow this year
Earnings results expected in 9 days
Fair Value
Day's Range
6.226.79
52 wk Range
6.0819.11
Key Statistics
Prev. Close
6.72
Open
6.75
Day's Range
6.22-6.79
52 wk Range
6.08-19.11
Volume
1.88M
Average Volume (3m)
2.22M
1-Year Change
-57%
Book Value / Share
6.91
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NEO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.05
Upside
+77.08%
Members' Sentiments
Bearish
Bullish
ProTips
9 analysts have revised their earnings downwards for the upcoming period

NeoGenomics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

NeoGenomics Inc Company Profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

NeoGenomics Inc SWOT Analysis


Strategic Crossroads
Neo Performance Materials faces pivotal decisions as it navigates market challenges and explores strategic alternatives, potentially reshaping its future in advanced materials
European Expansion
Delve into Neo's new agreement with a major European automotive supplier, signaling growth potential in the electric vehicle and green technology sectors
Market Dynamics
Explore the complexities of the rare earths market, including geopolitical factors, supply chain challenges, and Neo's positioning amidst industry volatility
Financial Outlook
Analysts project positive earnings for Neo, with Stifel setting a C$13.00 price target. The company's strategic review remains the primary value drive
Read full SWOT analysis

NeoGenomics Inc Earnings Call Summary for Q1/2025

  • Q1 2025 revenue of $168M missed forecast by $3.35M; EPS of $0 beat -$0.01 estimate
  • Stock dropped 19.66% pre-market despite 8% YoY revenue growth and 102% rise in adjusted EBITDA
  • Full-year revenue guidance maintained at $747-$759M, projecting 13-15% growth
  • CEO highlighted leadership in oncology solutions; expects revenue contributions from acquisitions
  • Analysts focused on sales force productivity timeline and Pathline integration during Q&A
Last Updated: 29/04/2025, 11:56 pm
Read Full Transcript

Compare NEO to Peers and Sector

Metrics to compare
NEO
Peers
Sector
Relationship
P/E Ratio
−10.4x−1.2x−0.5x
PEG Ratio
−1.18−0.090.00
Price/Book
0.9x1.7x2.6x
Price / LTM Sales
1.2x1.1x3.2x
Upside (Analyst Target)
92.3%53.0%44.3%
Fair Value Upside
Unlock21.9%6.6%Unlock

Analyst Ratings

8 Buy
6 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 11.05
(+77.08% Upside)

Earnings

Latest Release
Apr 29, 2025
EPS / Forecast
-- / -0.01
Revenue / Forecast
168.00M / 171.35M
EPS Revisions
Last 90 days

NEO Income Statement

People Also Watch

15.600
ZETA
-1.89%
11.270
RCAT
-7.70%
25.89
SM
-2.85%
113.59
FTAI
-1.78%
3.750
LAES
+0.27%

FAQ

What Is the NeoGenomics (NEO) Stock Price Today?

The NeoGenomics stock price today is 6.24

What Stock Exchange Does NeoGenomics Trade On?

NeoGenomics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for NeoGenomics?

The stock symbol for NeoGenomics is "NEO."

What Is the NeoGenomics Market Cap?

As of today, NeoGenomics market cap is 803.05M.

What Is NeoGenomics's Earnings Per Share (TTM)?

The NeoGenomics EPS (TTM) is -0.61.

When Is the Next NeoGenomics Earnings Date?

NeoGenomics will release its next earnings report on 28 July 2025.

From a Technical Analysis Perspective, Is NEO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has NeoGenomics Stock Split?

NeoGenomics has split 2 times.

How Many Employees Does NeoGenomics Have?

NeoGenomics has 2200 employees.

What is the current trading status of NeoGenomics (NEO)?

As of 20 July 2025, NeoGenomics (NEO) is trading at a price of 6.24, with a previous close of 6.72. The stock has fluctuated within a day range of 6.22 to 6.79, while its 52-week range spans from 6.08 to 19.11.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.